Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00302237 · ClinicalTrials.gov registry record
CAPTURE 2 Post-Marketing Registry
A clinical trial of Carotid Artery Disease, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 6,426
- Enrollment target
- 1
- Study location
NCT00302237: Completed study of Carotid Artery Disease, sponsored by Abbott Medical Devices.
NCT00302237 is a study of Carotid Artery Disease that has completed, run by Abbott Medical Devices. The registered enrollment target is 6,426 participants, below the 12,448-participant average among 5 other Carotid Artery Disease trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00302237, a study of Carotid Artery Disease, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 6,426 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of the registry are: 1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
Conditions Studied
Interventions
- DEVICE RX ACCULINK, RX ACCUNET Embolic Protection System
Study Locations (1)
California
- Abbott Vascular - Santa Clara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,426 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-05 |
What the finished NCT00302237 record still lists
NCT00302237 is an observational study that tracks outcomes without assigning an intervention. Its 6,426 participants enrollment target places it among the larger protocols in the corpus, below the 12,448-participant average among 5 other Carotid Artery Disease trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Carotid Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which RX ACCULINK, RX ACCUNET Embolic Protection System is the first listed.
NCT00302237 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00302237 about?
NCT00302237 is a clinical study titled "CAPTURE 2 Post-Marketing Registry". The purposes of the registry are: 1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the...
What is the current status of trial NCT00302237?
This trial is currently completed. The enrollment target is 6,426 participants. The study started on 2006-03. Estimated completion is 2010-05.
What conditions does trial NCT00302237 study?
This clinical trial studies the following conditions: Carotid Artery Disease.
What interventions are being tested in trial NCT00302237?
The interventions under investigation include: RX ACCULINK, RX ACCUNET Embolic Protection System (DEVICE).
Who is sponsoring clinical trial NCT00302237?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00302237 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carotid Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SVS VQI TransCarotid Revascularization Surveillance Project
RECRUITING
-
The Gore SCAFFOLD Clinical Study
COMPLETED · NA
-
Carotid Revascularization With ev3 Arterial Technology Evolution Post Approval Study
COMPLETED · NA
-
Assessment Of Vascular Health After Niacin Therapy (AVANT)
COMPLETED · NA
-
Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00505245 · 6,500 participants
New Assessment System in Measuring Symptom Distress in Cancer Patients
- NCT06821009 · 6,500 participants · NA
Effectiveness of a Cloud-based Digital Health Navigation Program for Colorectal Cancer Screening
- NCT05369429 · 6,516 participants · NA
My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life
- NCT04884802 · 6,254 participants · NA
The GUARDIAN Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia